Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Investor Presentation (May 2023)
15 slides from Alzecure Pharma Ab's investor presentation, May 17, 2023
Slide 1: Alzheimer's disease; Challenges & Opportunities
Alzheimer’s disease; Challenges & Opportunities Bengt Winblad, Professor Karolinska Institutet Dept NVS Center for Alzheimer Research Div of Neurogeriatrics AlzeCure, Solna, Sweden May 17, 2023
Slide 2: Dementia prevalence globally and in Sweden
Dementia prevalence globally and in Sweden Globally, more than 55 million people have dementia, of which Alzheimer disease may contribute to 60–70% of cases. - Every year, there are nearly 10 million new cases. Sweden: ▪ 150 000 persons with dementia, out of which -120 000 with Alzheimer disease, (9
Slide 3: Alzheimer's disease
Alzheimer’s disease Genetic factors Environmental /life style factors Mutations Genetic risk factors • APP (Chr 21) • ApoE4 (Chr 19) • Diet • Presenilin 1 (Chr 14) • Cholesterolemi • Presenilin 2 (Chr 1) • Hypertoni • Physical inactivity Amyloid beta plaques Sporadic AD Familial AD • 95-99 % of all
Slide 4: Therapy in AD: The first hundred years and looking forward
Therapy in AD: The first hundred years and looking forward………. Memantine NMDA Uncompetitive Receptor Antagonist 1906 1910 1974 1982 1997 2004 2010 2015 2021-2023 The Acetylcholinesterase cholinergic inhibitors hypothesis First Disease Modifying Rx aducanumab & lecanemab approved by FDA in US. Donane
Slide 5: 2021 Alzheimer drug development pipeline
2021 Alzheimer drug development pipeline ➢ “Biologics” are generally derived from living organisms and include antibodies, vaccines, antisense oligonucleotides, and therapeutic proteins. ➢ “Small molecules” refers to drugs taken orally that are typically <500 daltons in size and can regulate a biolo
Slide 6: Important with early diagnosis!
Important with early diagnosis! ▪ For the patient; ➔ Explanation of symptoms ➔ Practical future planning (eg economy, travels, retirement) ➔ Access to treatment before too much damage, take part in clinical trials ▪ For the relatives; ➔ Same as above ➔ Increased understanding ▪ For society; ➔ Patien
Slide 7: AD progress and biomarkers enables early diagnosis
AD progress and biomarkers enables early diagnosis Abnormal CSF Aβ42 Amyloid imaging FDG-PET MRI hippocampal FDG-PET volume MRI hippocampal CSF Tau volume Cognitive performance Function (ADL) CSF Aβ42 Cognitive performance Amyloid imaging Function (ADL) CSF Tau Normal Time Presymptomatic eMCI LMCI D
Slide 8: Addition of blood/plasma biomarkers
Addition of blood/plasma biomarkers C Teunissen, 2022, rev S Schedin-Weiss Bengt Winblad 18
Slide 9: Lecanemab phase study showed reduced amyloid burden over 8 months
Lecanemab phase 2 study showed reduced amyloid burden over 18 months (developed by BioArctic, Sweden) Global cortical average vs whole cerebellum reference PET SUVr 0.05 0.00 0.01 increase in PET Adjusted mean change from baseline(±SE) –0.05 SUVr –0.10 IMPROVEMENT –0.15 –0.20 0.22 reduction in PET –
Slide 10: Clarity AD (phase 3) Treatment Effect: CDR-SB
Clarity AD (phase 3)Treatment Effect: CDR-SB (Global Measure of Cognition and Function) Adjusted Clarity AD No. of Participants Mean % P (placebo, lecanemab) Difference Improvement Slowing Value CDR-SB Domains Favors lecanemab Memory 875, 859 -0.077 27.5 0.00117 CDR-SB Orientation 875, 859 -0.081 28
Slide 11: Donanemab – last reported positive immunotherapy study
Donanemab – last reported positive immunotherapy study ▪ Eli-Lilly, US reported in a press release May 3, 2023 positive top-line results of donanemab, from the phase 3 TRAILBLAZER-ALZ2 study ▪ Antibody treatment during 18 months targeting amyloid beta aggregates (plaques) in the brain ▪ 1,736 person
Slide 12: Lecanemab vs Donanemab
Lecanemab vs Donanemab ▪ Difference in study populations ▪ Different cognitive and ADL scales ▪ The only common scale is CDR-SB, but the outcome from this scale is also influenced by the different study populations In summary: ▪ These differences makes it difficult to properly compare the results fr
Slide 13: AlzeCure Pharma's two Alzheimer platforms
AlzeCure Pharma’s two Alzheimer platforms - 1st-in-class properties & potential game-changers Disease-modifying therapy Symptomatic therapy Alzstatin® NeuroRestore® Gamma-Secretase-Modulators Trk-PAMs Targeting Toxic Amyloid Production Improving Neuronal Function & Cognition - Novel Oral Small Molec
Slide 14: Research – still needed & the only way forward to new treatment
Research – still needed & the only way forward to new treatment Neuroprotection Risk inhibition Other molecules (growth factors, APOE, (life style, cholesterol, (ACD856, gene therapy, autophagy, inflammation) BRICHOS etc) Beta-amyloid Tau Neprilysin activation) All patients? Treatment of New finding
Slide 15: Acknowledgement
Acknowledgement ▪ Angel Cedazo-Minguez ▪ Vesna Jelic ▪ Lars Lannfelt ▪ Anders Wimo ▪ Gunilla Johansson Bengt Winblad 2023-05-17 15